Ozagrel (INN) is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.[1]
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.122.039 |
| Chemical and physical data | |
| Formula | C13H12N2O2 |
| Molar mass | 228.251 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Synthesis
edit
The free-radical halogenation of ethyl 4-methylcinnamate (1) with N-bromosuccinimide in the presence of benzoyl peroxide gives ethyl 4-bromomethylcinnamate (2).[2] Alkylation of imidazole (3) with this material gives the ethyl ester (4) of the drug, which is saponified to give ozagrel.[3][4]
References
edit- ^ Loo MH, Egan D, Vaughan ED, Marion D, Felsen D, Weisman S (March 1987). "The effect of the thromboxane A2 synthesis inhibitor OKY-046 on renal function in rabbits following release of unilateral ureteral obstruction". The Journal of Urology. 137 (3): 571–576. doi:10.1016/s0022-5347(17)44108-5. PMID 3820396.
- ^ US 4175203, Cragoe Jr EJ, Bicking JB, "nterphenylene 11,12-secoprostaglandins", issued 20 November 1979, assigned to to Merck and Co Inc
- ^ Iizuka K, Akahane K, Momose D, Nakazawa M, Tanouchi T, Kawamura M, et al. (October 1981). "Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives". Journal of Medicinal Chemistry. 24 (10): 1139–1148. doi:10.1021/jm00142a005. PMID 7199088.
- ^ "Ozagrel". Pharmaceutical Substances. Georg Thieme Verlag KG. Retrieved 2024-06-30.
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |